AstraZeneca ve Daiichi Sankyo'nun Meme Kanseri İlacı İngiltere'de NHS Kullanımı İçin Onaylandı

AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England

Tue, September 22, 2026 at 4:38 AM GMT+3 4 min read

• AZN +0.16%

AstraZeneca PLC (NYSE:AZN) and Daiichi Sankyo's Enhertu has been cleared for use by England's National Health Service (NHS) for patients with HER2-low metastatic breast cancer, reversing an earlier NICE decision that rejected funding on cost-effectiveness grounds. NICE's revised recommendation follows changes to drug valuation methods and a U.S.-UK agreement aimed at aligning medicine prices. Around 1,000 women in England are expected to benefit annually. Enhertu carries a list price of £1,455 per 100 mg vial, although the financial terms agreed with NICE were not disclosed. NICE cited clinical evidence showing a six-month survival benefit for some patients.

The decision comes as Enhertu is already becoming a significant growth driver for AstraZeneca. Combined Enhertu sales reported by AstraZeneca and Daiichi Sankyo reached $2.96 billion in the first half of 2026, up 29% from $2.29 billion a year earlier. AstraZeneca's own H1 alliance revenue from Enhertu rose to $1.06 billion from $834 million. In Europe, AstraZeneca reported $401 million of Enhertu revenue, up 28%, making NHS access an incremental opportunity within an already expanding franchise.

AstraZeneca Gains Wider Access for Its Fast-Growing Enhertu Franchise

The NHS decision expands access to Enhertu in one of Europe's largest healthcare markets and removes a previous reimbursement barrier. That could support additional patient uptake while strengthening Enhertu's position in HER2-low metastatic breast cancer. The timing is important because Enhertu is already growing rapidly: combined global sales increased 36% in FY2025 to $4.98 billion, while AstraZeneca PLC (NYSE:AZN)'s alliance revenue reached $1.80 billion, compared with $1.44 billion in 2024.

The decision also provides further validation for expanding Enhertu across earlier treatment settings and broader HER2 populations. AstraZeneca reported that H1 2026 Enhertu revenue increased 28% in the U.S., 45% in emerging markets, and 28% in Europe, with ongoing adoption in first-line HER2-positive breast cancer. The NHS reimbursement decision therefore adds to a broader pattern of geographic and indication expansion rather than representing an isolated launch.

Cost-Effectiveness Concerns Could Limit Enhertu's UK Economics

The direct financial contribution from England may remain relatively limited because NICE expects only around 1,000 women annually to receive the treatment. Moreover, the £1,455 vial price is a list price, while the actual commercial terms agreed with NICE were not disclosed. That makes it difficult to quantify the incremental revenue, margin, or cash-flow benefit for AstraZeneca from the decision.

There is also a potential pricing precedent. NICE initially rejected Enhertu because of cost-effectiveness concerns and subsequently changed its position after alterations to valuation methodology and the U.S.-UK pricing agreement. This suggests that broader public reimbursement can depend heavily on pricing concessions, potentially limiting the revenue captured per patient. The UK approval therefore does not necessarily translate into revenue growth at the headline list price. Meanwhile, Enhertu's strong existing growth means the incremental NHS opportunity is relatively small compared with the $1.72 billion of total Enhertu revenue AstraZeneca PLC (NYSE:AZN) recorded in H1 2026.

Conclusion

The NHS clearance is strategically supportive for AstraZeneca PLC (NYSE:AZN) because it removes a reimbursement obstacle for Enhertu and expands access to a rapidly growing oncology franchise. Enhertu's European revenue was already rising 28% in H1 2026, while AstraZeneca generated $1.06 billion in Enhertu alliance revenue during the period. The main limitation is scale: with roughly 1,000 eligible patients annually and undisclosed NHS pricing terms, the immediate financial impact is likely to be modest relative to AstraZeneca's overall business. The bigger significance is the additional market access and reinforcement of Enhertu's growth trajectory in breast cancer.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: Coca-Cola Bets $10 Billion on U.S. Infrastructure to Drive Growth and General Motors (GM) Bets on Software to Strengthen its Pickup Truck Franchise

This article is originally published at Insider Monkey.